Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Aaron Long

BSc (Hons)

Assistant Trial Manager

My role includes assisting the trial manager to ensure the successful recruitment of patients to a portfolio of clinical trials in the Cardiovascular & Renal theme hosted by the Department of Primary Care Health Sciences. The role involves having detailed knowledge of a number of projects within the Group’s diverse portfolio of CTIMPs and non-CTIMP studies and being able to manage competing demands and changing priorities. 

Main study: BARACK-D

Chronic kidney disease, a term commonly used by doctors to describe a long-term impairment in kidney function, frequently accounted for by the natural ageing process, is becoming increasingly common within the UK. It affects about 10% of the population. This is partly due to the fact that as a population we are living longer. However it is also because there are increases in other associated health problems including diabetes, obesity and high blood pressure. For these reasons, unlike many research studies, we are particularly interested in recruiting from the older age-group.

One of the concerns with chronic kidney disease is that it is linked to an increased chance of developing heart disease. This is because the kidneys are less effective at getting rid of waste products and excess fluid from the body. This in turn causes the heart to function less effectively. At the moment there are very few treatments available which reduce the amount of kidney damage and heart disease in people with chronic kidney disease.
In this trial we are looking at a drug called spironolactone to see whether it helps reduce heart disease and kidney damage in people with chronic kidney disease. Other studies have suggested that similar drugs may have this effect.